<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (MDSs) are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:e sem="disease" ids="C0005940" disease_type="Disease or Syndrome" abbrv="">diseases of bone</z:e> marrow (BM) cell precursors for which immunophenotypic characterization is still considered irrelevant despite the accuracy and sensitivity of flow cytometry techniques </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to determine whether immunophenotypic abnormalities could be defined in MDSs and could correlate with the French-American-British classification and cytogenetics </plain></SENT>
<SENT sid="2" pm="."><plain>Analysis was performed on 275 BM samples (207 MDS patients, 68 controls) and 25 control blood samples </plain></SENT>
<SENT sid="3" pm="."><plain>Immunophenotyping was based on a primary gating of blast cells, monocytes, and granulocytes according to CD45 antigen expression and side scatter light diffraction </plain></SENT>
<SENT sid="4" pm="."><plain>Immunophenotypic hierarchical clustering was performed to analyze the results </plain></SENT>
<SENT sid="5" pm="."><plain>The data obtained show that (1) immunophenotypic clustering partly discriminates patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts/<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>/<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) for CD45(lo) blast cells and patients with RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> for CD45(hi)/side scatter(hi) (SS(hi)) granulocytes; (2) the most discriminating markers were CD16, CD34, CD36, CD38, CD71, and HLA-DR for blast cells and CD11b, CD13, CD33, CD36, CD38, CD71, and HLA-DR for CD45(hi)/SS(hi) granulocytes; (3) clusters related to CD34 expression were associated with high levels of blast cells on BM smear; (4) clusters related to high levels of CD36 expression on CD45(lo) blast cells and CD45(hi)/SS(hi) granulocytes were associated with a poor International Prognosis Scoring System score; and (5) high levels of CD71 expression on CD45(hi)/SS(hi) granulocytes were associated with the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> category </plain></SENT>
<SENT sid="6" pm="."><plain>These results show a close relationship between immunophenotypic abnormalities and BM <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and suggest that flow cytometry could be a future tool for the characterization of MDSs </plain></SENT>
</text></document>